Join our daily newsletter At The Bell to receive exclusive market insights
- Hexima’s (HXL) shares have taken a hit today after phase two preliminary results for its pezadeftide drug came back inconclusive
- The company says the results from the trial do not support a move to phase three trials, with data showing no correlation to the previous phase one study
- The anti-infective focused biotech company plans to review the clinical data and study conduct and will report the findings once complete
- HXL dropped sharply by 83.1 per cent to 4.4 cents each at market close
Hexima’s (HXL) shares have taken a hit today after phase two preliminary results for its pezadeftide drug came back inconclusive.
Pezadeftide aims to treat onychomycosis, a fungal nail infection that causes discolouration, thickening, and separation from the nail bed.
The company said the results from the trial do not support proceeding directly to phase three trials, with data showing no correlation to the previous phase one study.
Hexima plans to review the clinical data and study conduct and will report the findings once complete.
In its last quarterly report, the anti-infective focused biotech company stressed the importance of the phase two trial.
“This study is central to Hexima’s development program because it is intended to provide critical information on the safety and efficacy of topical two per cent pezadeftide in treating onychomycosis and to provide data to determine which treatment approach is the safest, most effective and convenient for patients,” it said.
As its leading product candidate, the news sent shares plummeting.
HXL dropped sharply by 83.1 per cent to 4.4 cents each at market close.
